Biocept
Biocept Q2 Revenues Continue COVID-19-Driven Spike
The company saw a slowdown in its virus testing from Q1 but still dwarfed its Q2 2020 results, as COVID-19 assays continued to outweigh its core cancer business.
Biocept HER2 Assay Gains Coverage Under Medicare Local Coverage Determination for CTC Tests
Under the LCD, CTC assays, such as Biocept's, will now be covered to guide targeted treatment decisions for patients with breast and other cancers under certain circumstances.
Quest Diagnostics to Offer Biocept's Target Selector NGS Lung Cancer Test
The liquid biopsy test is intended for identifying genetic mutations to guide therapy in patients with advanced non-small cell lung cancer.
Biocept, Cleared4 Partner to Provide COVID-19 Testing, Management Service
The companies are developing a system using Cleared4's health validation platform to allow Biocept COVID-19 customers to monitor and manage their testing programs.
Mar 31, 2021
May 13, 2020
Biocept Q1 Revenues Up 41 Percent
Apr 27, 2020
Biocept Files $100M Shelf Registration
Apr 14, 2020